Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

International Parkinson and Movement Disorder Society
Main Content

Recent Developments in Gene Targeted and Immunotherapies of Parkinson's Disease

Presented by

Roy N. Alcalay, MD
Joseph Quinn, MD
Carlos Singer, MD

Course Description

The treatment of Parkinson’s disease (PD) has thus far been restricted to symptomatic therapies. These treatments improve quality of life but do not address PD’s relentless progression.

The discovery of genetic mutations that cause or increase the risk of development of PD has opened the possibility of genetically targeted therapies with the potential of slowing or stopping the progression of specific monogenetic forms of PD.  Further, the possibility that misfolded synuclein aggregation is a key pathogenetic factor in PD has culminated in ongoing trials of synuclein-targeted immunotherapies with a similar potential benefit for all forms of PD, be they genetic or sporadic.

This webinar will review the current state of affairs of clinical trials of both these types of therapies. The lectures will cover the pharmacology and recent results of relevant clinical trials, as well as their future directions.

Target Audience

This course is intended for neurologists interested or specializing in Movement Disorders.

Learning Objectives
  1. Describe the different mechanisms of action of the gene and synuclein targeted therapies of PD
  2. Explain the current state of development of clinical trials of both therapies
  3. Recognize the use of biomarkers to monitor target engagement and effect on progression of PD
  4. Identify future directions of these novel therapeutic modalities